Evidence map›Paper›PMID 30269214›Full record

ReviewApplied microbiology and biotechnology2018

Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors.

Francesca Marino-Merlo, Beatrice Macchi, Daniele Armenia, Maria Concetta Bellocchi, Francesca Ceccherini-Silberstein, Antonio Mastino, Sandro Grelli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesca Marino-Merlo *IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy.
Beatrice Macchi *Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Daniele ArmeniaDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Maria Concetta BellocchiDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Antonio MastinoDepartment of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Via F. Stagno d'Alcontres 31, 98166, Messina, Italy. antonio.mastino@unime.it.ORCID http://orcid.org/0000-0002-0338-6450
Sandro GrelliDepartment of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The biology of HIV is rather complex due to high rate of replication, frequent recombination, and introduction of mutations. This gives rise to a number of distinct variants referred as quasispecies. In addition, the latency within reservoir allows the periodic reactivation of virus replication. The rapid replication of HIV allows immune response escape and establishment of resistance to therapy that can be acquired through drug selection and/or transmitted among individuals. This prompted, over the years, the development of a range of assays aimed to determine drug resistance and sensitivity, to be used both in clinical practice and in antiviral research. Reverse transcriptase (RT) inhibitors have an eminent place among the anti-HIV drugs, being constantly present from the beginning until today in the most commonly used antiviral regimens. This mini-review seeks to provide an up-to-date overview of recent efforts in developing even more reliable and simple methods, of both genotypic and phenotypic types, for specifically detecting drug resistance and sensitivity to RT inhibitors.

Indexed as

Diagnostic Tests, RoutineDrug Resistance, Multiple, ViralGenotyping TechniquesHIV-1HIV InfectionsHumansReverse Transcriptase InhibitorsVirus ReplicationReverse Transcriptase InhibitorsHIVNon nucleoside reverse transcriptase inhibitorsNucleoside reverse transcriptase inhibitorsReverse trancriptase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.